RSV vaccines | NITAG RESOURCE CENTER

Is there a Gavi programme to support the introduction of this vaccine? If a Gavi programme is available, what support is available to countries?

Both the maternal vaccines and infant mAbs were approved in the 2018 Gavi Vaccine Investment Strategy. These are to be re-visited at Gavi board in Q4 2025. Only the maternal vaccine has a Gavi price commitment currently and Gavi co-funding and other support is yet to be determined. ^{Go to footnote 11, Go to footnote 22}

Sources

Go back to footnote reference 1
Gavi, the Vaccine Alliance (2018). Report to the Board, 28–29 November 2018: vaccine investment strategy. Geneva: Gavi, the Vaccine Alliance (https://www.gavi.org/sites/default/files/board/minutes/2018/28-nov/docs/08%20-%20Vaccine%20Investment%20Strategy%20document.pdf, accessed 20 June 2025).
Go back to footnote reference 2
Gavi, the Vaccine Alliance (2025). Gavi welcomes first-ever prequalification of maternal RSV vaccine. Geneva: Gavi, the Vaccine Alliance (https://www.gavi.org/news/media-room/gavi-welcomes-first-ever-prequalification-maternal-rsv-vaccine, accessed 20 June 2025).